Oruka Therapeutics (ORKA) Projected to Post Earnings on Thursday

Oruka Therapeutics (NASDAQ:ORKA) will likely be issuing its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of ($0.68) per share for the quarter.

Oruka Therapeutics Price Performance

ORKA stock opened at $12.07 on Thursday. The firm has a market capitalization of $422.44 million, a price-to-earnings ratio of -1.93 and a beta of 0.81. Oruka Therapeutics has a 52-week low of $10.95 and a 52-week high of $53.88. The company’s 50 day moving average price is $18.69.

Analyst Upgrades and Downgrades

ORKA has been the topic of several recent analyst reports. Stifel Nicolaus assumed coverage on shares of Oruka Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $49.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday, December 20th. Finally, Wedbush reissued an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Oruka Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $43.17.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.